<DOC>
	<DOCNO>NCT02319590</DOCNO>
	<brief_summary>The study aim 1 ) determine autoantibody titer AGTR1 receptor ETA receptor , 2 ) characterize cytokine expression profile heart-specific activated T cell patient systolic heart failure . Auto-antibody titer specific cytokine expression profile heart-specific activated T cell correlate heart failure progression outcome .</brief_summary>
	<brief_title>Anti-Angiotensin-Receptor 1 ( ATR1 ) - , Anti-Endothelin-Receptor A ( ETRA ) -Antibodies T Cells Cardiomyopathy</brief_title>
	<detailed_description>1 . AIM OF THE STUDY 1.1 . Background Progressive interstitial fibrosis parallel pathological remodel fail heart . This particularly case patient post-inflammatory dilated cardiomyopathy , also observe ischemic hypertensive heart disease . Both , Angiotensin II ( AngII ) Endothelin-1 ( ET1 ) induce formation profibrotic cytokine TGFβ promote fibrosis . From point view , surprise block Renin-Angiotensin-Aldosterone-System ( RAAS ) evolve key strategy slow heart failure progression . Furthermore , recent data also point important role Angiotensin II signal heart failure preserve ejection fraction . In animal model , block effect AngII ET1 reduce fibrotic remodel follow myocardial ischemia pulmonal hypertension . In line finding , find evidence fibrotic remodel AGTR1-/- mouse recover acute myocarditis . Nevertheless , RAAS blockade efficient enough completely prevent heart failure progression even rapid deterioration subgroup affect patient . Only recently , Riemekasten et al demonstrate auto-antibodies AGTR1 ETAR increase systemic sclerosis associate increase pulmonary hypertension lung fibrosis ( 2 ) . Moreover , auto-antibodies show functional active induce downstream expression TGFβ -mRNA . Anti-AGTR1-Ab Anti-ETAR-Ab might therefore directly promote fibrosis activation AGTR1 ETAR . Furthermore , auto-reactive T-cells myosin heavy chain ( MyHC ) heart muscle demonstrate play important role initial inflammation myocarditis well progression inflammation . 1.2 . Rationale current study Cardiac autoantibody titer generally elevate patient myocardial infarction suffer systolic heart failure . In addition , find experimental evidence critical role AngII signal development cardiac fibrosis . We hypothesize auto-immunological effect general , Anti-AGTR1-Ab , Anti- ETAR-Ab auto-reactive T-cells particular , important far widely underestimated pathogenesis cardiomyopathy interfere evidence base treatment approach . 1.3 Aims The objective study - determine concentration Anti-AGTR1- Anti-ETRA-AB patient blood . - determine auto-reactive heart specific T-cells cytokine expression profile patient blood . - correlate finding outcome ( hospitalization due heart failure , stroke , myocardial infarction , death ) cardiac function patient ( VO2 , Ejection fraction , NYHA class ) . 2 . STUDY DESIGN Prospective pilot study . 3 . PARTICITPANT ENTRY 3.1 . Pre -- ‐registration evaluation Patients cardiomyopathy heart failure 6 month recruit GZO Spital Wetzikon ambulatory visit . 4 . EFFICACY AND SAFETY VARIABLES 4.1 . Efficacy variable examination 4.1.1 non -- ‐study specific variable examination Medical history - general information : age , gender , weight , height - actual medication - stag heart failure accord severty symptom physical activity ( New York Heart Association-classification ) Electrocardiogram ( ECG ) For electrocardiographic recording commercially available 12-lead ECG use set 25mm/s paper speed 10mm/mV amplitude . Transthoracal echocardiography ( TTE ) TTE perform cardiologist . The following parameter record : - Left ventricular ejection fraction use Simpson Biplan method - Left ventricular end diastolic end systolic diameter - Left atrial diameter - Peak velocity E , A ; E/A quotient ; TDI - Flow pulmonary veines 4.1.2 Study specific variable examination Determinations Anti-AGTR1-AB Anti-ETRA-AB Concentrations Anti-AGTR1-AB Anti-ETRA-AB measure use commercially available ELISA-Kits accord manufacture protocol ( Celltrend , Luckenwalde , Germany ) . Evaluation auto-reactive T-Cells Auto-reactive T-cells isolated patient blood analyse describe organ-specificity ( cMET+ ) , reactivity cardiac self-antigens cytokine expression profile . 5 . ASSESSMENT AND FOLLOW -- ‐UP The investigation visit describe paragraph 4 . The assessment perform initial visit , 4 month , 12 month . 6 . STATISTICS AND DATA ANALYSIS As pilot study publish data observe parameter cardiomyopathy available , power analysis perform . Groups compare use ANOVA . Statistical significance assume probability p &lt; 0.05 . 7 . REGULATORY ISSUES 7.1 Ethic approval The study conduct accord current declaration Helsinki , Good Clinical Practice-guidelines Swiss regulatory authority´s requirement . The study approve KEK ( local ethic committee ) . 7.2 Consent Written consent seek participant full explanation study time allow consideration . The right participant refuse participate without give reason respect . If participant withdrawls his/her consent , data collect date withdrawal use . 7.3 Confidentiality All study personnel preserve confidentiality participant take part study . 7.4 Insurance Insurance cover `` Zurich Versicherungsgesellschaft AG '' GZO Spital Wetzikon . 8 . QUALITY CONTROL 8.1 Audits The investigator welcome audit regulatory body ensure adherence GCP regulatory requirement . 8.2 Data management A designate research nurse and/or research fellow responsible data collection data management . 8.3 Data privacy Access personal data participant strictly limit investigator aforementioned . Raw data archieved least 10 year . Blood sample willbe analyse Center Molecular Cardiology University Zurich group cardioimmunology destroy definitive analysis . Blood sample collection do GZO Spital Wetzikon . The blood sample anonymised directly collection . All data sheet , blood sample data fromanalysis anonymised two-digit code . The key match two-digit-code personal data patient store separate , password-protected data base . Only principal investigator investigator Dr. med . Nazmi Krasniqi access data base .</detailed_description>
	<mesh_term>Cardiomyopathies</mesh_term>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<criteria>Aged 18 85 Left ventricular ejection fraction &lt; 35 % Established medical heart failure therapy Informed consent mental physical disability precluding inform consent compliance protocol . Active autoimmune disease ( rheumatoid arthritis , systemic sclerosis , sytemic lupus erythematodes , polymyositis others ) Active infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>